Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas

DCs are the most potent APCs and are the focus of many immunotherapeutic approaches for the treatment of cancer, although most of these approaches require the ex vivo generation and pulsing of DCs. We have targeted a subset of DCs in vivo using an Ab to DNGR-1, a C-type lectin dedicated to the cross...

Descripción completa

Detalles Bibliográficos
Autores principales: Picco, Gianfranco, Beatson, Richard, Taylor-Papadimitriou, Joyce, Burchell, Joy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Cellular Immune Response
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209794/
https://www.ncbi.nlm.nih.gov/pubmed/24648154
http://dx.doi.org/10.1002/eji.201344076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209794/
https://www.ncbi.nlm.nih.gov/pubmed/24648154
http://dx.doi.org/10.1002/eji.201344076

Ejemplares similares